CSIMarket
 
Ispecimen inc   (ISPC)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.4800 $0.03 6.904%
Day's High: $0.49 Week Perf: 9.04 %
Day's Low: $ 0.46 30 Day Perf: 0.9 %
Volume (M): 22 52 Wk High: $ 2.05
Volume (M$): $ 11 52 Wk Avg: $1.00
Open: $0.49 52 Wk Low: $0.40



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 9
 Employees -
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 5

Ispecimen Inc
Ispecimen Inc. is a technology company that specializes in providing biospecimen supply and data services to the healthcare and life sciences industries. They have developed a unique platform that enables researchers and drug developers to access and obtain high-quality human biospecimens for their research and development activities. These specimens include blood, tissue, and other biological materials, which are crucial for advancing medical breakthroughs and improving patient care. Ispecimen Inc. also offers data services, where they aggregate and standardize clinical and research data to create valuable insights for their clients. By connecting healthcare providers, patients, and researchers, Ispecimen Inc. aims to accelerate the pace of medical research and ultimately contribute to better diagnostics, treatments, and cures for various diseases.


   Company Address: 450 Bedford Street, Lexington, 2420 MA
   Company Phone Number: 301-6700   Stock Exchange / Ticker: NASDAQ ISPC
   ISPC is expected to report next financial results on March 20, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Partnership

iSpecimen, a leading supplier of human biospecimens, and TriMetis Life Sciences, a pioneer in digital AI histopathology services, have announced a strategic partnership aimed at revolutionizing tissue-based research By leveraging cutting-edge technology and expertise, these two companies aim to optimize quality control and assurance, ultimately enhancing the efficiency and accuracy of histopathology services

Published Tue, Jan 23 2024 12:30 PM UTC

iSpecimen, a leading supplier of human biospecimens, and TriMetis Life Sciences, a pioneer in digital AI histopathology services, have announced a strategic partnership aimed at revolutionizing tissue-based research. By leveraging cutting-edge technology and expertise, these two companies aim to optimize quality control and assurance, ultimately enhancing the efficiency and ...

Product Service News

Revolutionizing Oncology Research: iSpecimen Expands Global Biospecimen Offering, Boosting Access to Vital Research Materials

Published Thu, Dec 7 2023 12:30 PM UTC



In an endeavor to advance the field of oncology research, iSpecimen Inc has reinforced its global biospecimen offering by adding new suppliers and expanding existing relationships. This strategic move aims to provide researchers with increased access to highly-sought-after biospecimens, thereby stimulating innovation and expediting breakthroughs in cancer treatment...

Ispecimen Inc

Ispecimen Inc. Bounces Back: Third Quarter of 2023 Earnings Show Promising Redemption from Diminishing Returns



As the third quarter of the 2023 earnings season unfolds, Ispecimen Inc. (ISPC) reveals impressive improvements in its financial performance. The medical laboratories company has managed to decrease its loss per share, boost its revenue, and reduce its net deficit compared to the previous year. These positive results come as a beacon of hope in the face of industry-wide challenges. However, despite the company's recent uptick in share value, it still faces an uphill battle to fully recover from its year-to-date declines.
Improving Financials
ISPC has made significant strides in improving its financial situation. In the third quarter of 2023, the company reported a loss per share of $-0.23, which represents a noteworthy improvement compared to the $-0.39 loss per share recorded in the previous quarter. Furthermore, when compared to the same quarter last year, ISPC reduced its loss per share from $-0.35, demonstrating a clear path towards profitability.

Ispecimen Inc

iSpecimen Inc Sees Major Revenue Decline in Q2 2023 Amid Shrinking Orders

Weak orders have caused Ispecimen Inc to experience growth in losses for the April to June 30, 2023 period. The company's net loss per share increased from $-0.30 to $-0.39, while revenue decreased by -30.511% from $2.34 million to $1.63 million compared to the previous year.
This decline in business is in contrast to the overall performance of the Medical Laboratories sector, which posted revenue growth during the same period. Ispecimen Inc's revenue tumbled even further in comparison to the first quarter, with a -44.914% decrease from $2.95 million. Additionally, the company's deficit per share grew from $-0.25.

Ispecimen Inc

ISPC Reports Revenue Growth and Improved ROI Ranking in Q1 2023

Ispecimen Inc has recorded a cumulative net loss of $-10 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -44.81%.
Within the healthcare sector, 178 other companies had a higher ROI. However, the overall ranking of ROI has progressed in the Mar 31 2023 quarter, so far to 1478 from a total ROI ranking in the fourth quarter of 2022 of 3768.
For the fiscal time-frame ending March 31 2023, ISPC lost money of $-0.25 per share, compared to $-0.27 a year before. The company's revenue increased considerably by 17.134% to $2.95 million from $2.52 million in the comparable reporting period a year prior. However, sequentially, revenue decreased by -0.383% from $2.96 million.






 

Ispecimen Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com